Several drugs used for curing hepatitis C have been identified as potential candidates to treat COVID-19, according to research conducted using the MOGON II supercomputer at Johannes Gutenberg University Mainz.
Daniel Berman, Head of Global Health, Nesta Challenges, highlights the need for radical change in how innovation is funded and prioritised to ensure an antibiotic future given AMR is still climbing, even though behaviours are changing.
In the view of Amanda Feilding, Founder of the Beckley Foundation, “Psychedelics are unique pharmacological compounds that hold the promise of a profound paradigm shift in psychiatry.” Here, we learn about the Psychedelic Renaissance and the importance of drug policy reform.
Here, we look at medical devices policy of Japan’s Ministry of Health, Labour and Welfare. The Ministry now has Katsunobu Katō in place, who very recently replaced Nemoto Takumi as the Minister of Health, Labour and Welfare in the country.
Prof Colin J Suckling OBE DSc FRSE from the Department of Pure & Applied Chemistry, at University of Strathclyde, explains the importance of getting your chemistry right.
Koichi Watashi, Senior Researcher from the National Institute of Infectious Diseases, Japan, explores the trick for cell invasion in reaching regulation of hepatitis B entry.
Chiara Frazzoli and Alberto Mantovani from Istituto Superiore di Sanità share their insights into endocrine disruptors and non-communicable diseases in Africa, in collaboration with NOODLES Alliance Network.
The EU-funded project FLEXPOL (GA number 721062) offers an affordable approach to prohibit the spread of bacteria and healthcare-associated infections using cost-effective and sustainable film products.
Prof Dr Freimut Schliess, Director, Science & Innovation at Profil GmbH, sheds light on how Clinical Contract Research Organisations are building the digital bridge connecting clinical research and clinical care.
Diabetes UK and JDRF have announced their continued commitment to revolutionising Type 1 diabetes treatment, by awarding £490,000 to fund the next generation of immunotherapy research.
King's College London researchers found that cannabidiol (CBD) could hold promise as a treatment for psychosis, according to reasonable benefits seen in a clinical trial.
